GlassScriptPhysician profile
Farah Farah
NPI 1720405038
$968.75
in general payments reported to CMS, 2019-2025
16 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $110 · 2021: $117 · 2022: $120 · 2023: $173 · 2024: $46.09 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $396.06 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.97 | 2019 | |
| Dexcom, INC. | $94.10 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $83.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.34 | 2019-2025 | Xifaxan |
| Mannkind Corporation | $33.05 | 2022 | |
| Lifescan, INC. | $29.45 | 2023 | |
| Melinta Therapeutics, LLC | $27.21 | 2019 | |
| Pfizer INC. | $24.94 | 2020 | |
| Recordati_rare_diseases_inc. | $20.75 | 2025 | Isturisa |
| Alvogen INC | $20.59 | 2023 | Teriparatide |
| Sequel Med Tech, LLC | $20.17 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $19.00 | 2023 | Unithroid |
| Cipher Pharmaceuticals US LLC | $15.19 | 2025 | Spinosad, Natroba |
| Alexion Pharmaceuticals, INC. | $14.34 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.